Avidity tops up IPO at $298M; Bristol Myers keeps a Celgene discovery pact alive
→ The underwriters of Avidity Biosciences’ IPO have exercised their option to purchase additional shares, bringing the total amount raised …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
